Vigil Neuroscience is a subsidiary of Amgen Inc. that focuses on developing disease-modifying therapeutics for neurodegenerative diseases. Their lead product candidate, VGL101, is a monoclonal antibody designed to activate TREM2 and is being tested for the treatment of leukoencephalopathy, adrenoleukodystrophy, and Alzheimer's disease. They also develop a small molecule TREM2 agonist for oral delivery. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.